How Sugar Modifications Shape Cell Function and Disease
Sialylation, a post-translational modification, entails the covalent addition of sialic acid residues to the terminal ends of glycoconjugates. Sialic acids represent a diverse family of negatively charged nine-carbon monosaccharides typically located at the terminal positions of glycoproteins and glycolipids. Their strategic position at the end of the oligosaccharides confers critical roles in modulating cellular communication, adhesion, and immune recognition. More than 50 structurally distinct sialic acids have been identified to date, with N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) constituting the predominant forms in mammals. [1]
Sialylation can occur through α-2,3- or α-2,6-linkages to galactose (Gal) or N-acetylgalactosamine (GalNAc), as well as α-2,8- or α-2,9-linkages between sialic acid residues, thereby generating polysialic acid (PolySia) structures. [2] The degree and type of terminal sialylation critically influence glycoprotein stability, as increased sialylation enhances serum half-life by preventing recognition by the asialoglycoprotein receptor and subsequent hepatic clearance.
Biological Functions of Sialic Acids
- Anti-adhesive properties
Terminal sialylation contributes to the electrostatic repulsion between cells, thereby functioning as an anti-adhesive determinant. [3] For instance, erythrocytes, with their dense sialylation, exhibit a strong negative surface charge that prevents aggregation. Similarly, endothelial luminal surfaces enriched in sialic acid residues create a repulsive barrier that facilitates the free passage of erythrocytes through the vasculature. - Mediators of receptor interactions
Sialic acids act as recognition motifs for lectins, particularly sialic acid-binding immunoglobulin-like lectins (Siglecs) and selectins. [4] Selectins, for example, govern leukocyte rolling and trafficking by recognizing the sialyl-Lewis X (sLex) epitope, which is generated by α-2,3-sialylation of lactosamine followed by α-1,3-fucosylation.
Sialylation in Physiological Processes
Regulation of complement activation
Sialylated glycans modulate the alternative complement pathway through the recruitment of factor H, which discriminates self from non-self structures. Recognition is influenced by both the glycosidic linkage type and side-chain modifications, such as O-acetylation, that alter factor H binding affinity. [5]
Roles in immune regulation
Siglecs expressed on immune cells modulate both pro- and anti-inflammatory signaling. For example, Siglec-G and Siglec-E engagement dampens inflammatory responses, while Siglec-14 to -16 activation promotes proinflammatory signaling pathways. In contrast, Siglec-2, -3, and -5 to -11 interactions suppress toll-like receptor signaling. For example, desialylation of tumor cell glycans unmasks galactose residues that serve as “eat-me” signals, facilitating phagocytosis. [6]
Influence on antibody function
Sialylation of the Fc region of immunoglobulins alters antibody effector functions. Human IgG predominantly carries α-2,6-linked sialic acids, and higher Fc sialylation correlates with reduced antibody-dependent cellular cytotoxicity (ADCC). [7,8]
Sialylation also influences protease sensitivity, dendritic cell maturation, platelet function, stem cell pluripotency, and sperm development and fertilization. [1]
Sialylation in Pathological Processes
Aberrant sialylation, or hypersialylation, is a hallmark of numerous malignancies and is characterized by alterations in sialic acid content, sialidase activity, sialyltransferase expression, and the abundance of sialoglycoproteins. Elevated sialylation enhances tumor cell resistance to apoptosis, supports uncontrolled proliferation, and facilitates metastatic potential. [1]
Clinical studies have reported increased total serum or plasma sialic acid concentrations during cancer initiation, progression, and therapy. This hypersialylated phenotype contributes to cancer aggressiveness by modulating cell–cell interactions, altering extracellular matrix adhesion, and enhancing migratory and invasive capacities. In fact, sialylation alterations are involved in every stage of metastasis: detachment from the primary tumor, intravasation and survival in circulation, lymphatic dissemination, and colonization of distant organs.
During tumor progression, sialylated antigens function as “don’t-eat-me” signals by engaging inhibitory Siglecs on macrophages, thereby suppressing phagocytosis. Many tumor-associated antigens are heavily sialylated, which contributes to immune evasion and sustained tumor growth.
Since sialylation plays such a critical role in cancer development, several strategies have been proposed, including the blockade of sialylation, targeting SIGLECs or selectins, delivering sialidases directly to the tumor microenvironment to overcome immune evasion, and developing cancer vaccines based on tumor-specific sialic acid–containing structures.[9]
Sialylation-based strategies have also been explored for applications beyond cancer, such as in the treatment of viral infections—due to virus–cell interactions mediated by sialic acids—as well as for therapies targeting central nervous system disorders and stroke.
Conclusions
Sialylation is essential for regulating immune system functions such as complement activation, leukocyte trafficking, dendritic cell maturation, and antibody modulation. It also supports the maintenance of stem cell characteristics and fertility. However, sialic acids can be hijacked by pathogens and tumor cells for their advantage. Aberrant sialylation has been associated with cancer progression, central nervous system disorders, viral infections, atherosclerosis, and cardiovascular diseases. Consequently, new therapeutic approaches targeting the sialylation pathway are being explored. Inhibitors of sialyltransferases, selectins, and SIGLECs have shown promise in animal cancer models, and sialidase-conjugated antibodies are now advancing into clinical trials for cancer therapy.
Understanding the complexity and biological significance of sialylation requires precise analytical tools capable of characterizing glycan structures and their functional implications. Asparia Glycomics provides advanced glycomics profiling and Glycan Analysis Services that enable researchers to identify, quantify, and characterize sialylated glycoconjugates across a wide range of biological samples. By combining high-resolution mass spectrometry, glycan mapping, and specialized sialic acid analysis workflows, Asparia helps uncover alterations in sialylation associated with disease progression, immune regulation, and therapeutic response. Additionally, our Custom Glycan Synthesis Services enable the design and production of specific sialylated glycan structures tailored to your research needs.
References
- Zhu, W.; Zhou, Y.; Guo, L.; Feng, S. Biological Function of Sialic Acid and Sialylation in Human Health and Disease. Cell Death Discov. 2024, 10 (1), 415. https://doi.org/10.1038/s41420-024-02180-3.
- Angata, T.; Varki, A. Chemical Diversity in the Sialic Acids and Related α-Keto Acids: An Evolutionary Perspective. Chem. Rev. 2002, 102 (2), 439–470. https://doi.org/10.1021/cr000407m.
- Varki, A. Sialic Acids in Human Health and Disease. Trends Mol. Med. 2008, 14 (8), 351–360. https://doi.org/10.1016/j.molmed.2008.06.002.
- Smith, B. A. H.; Bertozzi, C. R. The Clinical Impact of Glycobiology: Targeting Selectins, Siglecs and Mammalian Glycans. Nat. Rev. Drug Discov. 2021, 20 (3), 217–243. https://doi.org/10.1038/s41573-020-00093-1.
- Blaum, B. S.; Hannan, J. P.; Herbert, A. P.; Kavanagh, D.; Uhrín, D.; Stehle, T. Structural Basis for Sialic Acid–Mediated Self-Recognition by Complement Factor H. Nat. Chem. Biol. 2015, 11 (1), 77–82. https://doi.org/10.1038/nchembio.1696.
- Gonzalez-Gil, A.; Schnaar, R. L. Siglec Ligands. Cells 2021, 10 (5), 1260. https://doi.org/10.3390/cells10051260.
- Scallon, B. J.; Tam, S. H.; McCarthy, S. G.; Cai, A. N.; Raju, T. S. Higher Levels of Sialylated Fc Glycans in Immunoglobulin G Molecules Can Adversely Impact Functionality. Mol. Immunol. 2007, 44 (7), 1524–1534. https://doi.org/10.1016/j.molimm.2006.09.005.
- Vajaria, B. N.; Patel, K. R.; Begum, R.; Patel, P. S. Sialylation: An Avenue to Target Cancer Cells. Pathol. Oncol. Res. 2016, 22 (3), 443–447. https://doi.org/10.1007/s12253-015-0033-6.
- Garabedian, B. M.; Bashian, E. E.; Wang, X.; Thompson, A. J.; Paulson, J. C. Targeting Sialidase to PD1 Enhances T Cell Function and Tumor Control. ACS Cent. Sci. 2025, 11 (8), 1417–1427. https://doi.org/10.1021/acscentsci.5c00510